antibody-based targeting of bcma in multiple myeloma
Published 4 years ago • 141 plays • Length 4:27Download video MP4
Download video MP3
Similar videos
-
1:38
using bcma-targeting agents in earlier lines of treatment for multiple myeloma
-
2:31
integrating bcma-targeted agents in earlier lines of therapy for r/r multiple myeloma
-
2:31
the value of bcma-targeting therapy in multiple myeloma: current applications and future outlooks
-
0:41
fcrh5 & gprc5d bispecific antibodies: antigen targets beyond bcma for multiple myeloma
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma
-
43:39
antigen presentation, t cell activation and deactivation
-
5:02
blood review series: therapeutic antibodies
-
5:00
monoclonal antibodies and their mechanism of action
-
1:45
targetting bcma in myeloma
-
1:37
integrating bcma-targeted immunotherapies into challenging multiple myeloma cases
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
2:19
sequencing bcma-targeted agents in multiple myeloma
-
1:29
sequencing bcma-targeted therapies in myeloma
-
1:10
the importance of bcma, fcrh5 and gprc5d in multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
1:02
managing progression after bcma-targeted therapy in r/r multiple myeloma
-
1:47
role of bcma-targeting adcs in the management of myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
1:24
disparities in access and practice patterns of bcma-directed therapies in multiple myeloma